Suppr超能文献

疑似抗磷脂综合征患者改良凝血酶原生成试验测定各种抗磷脂抗体的血栓形成水平。

Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome.

机构信息

Masaryk Hospital Usti nad Labem, Department Clinical Hematology, 40113 Usti nad Labem, Czech Republic.

Department of Hemato-Oncology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacky University Olomouc, 77900 Olomouc, Czech Republic.

出版信息

Int J Mol Sci. 2022 Aug 11;23(16):8973. doi: 10.3390/ijms23168973.

Abstract

Antiphospholipid syndrome (APS) is a hypercoagulable state accompanied by the presence of heterogeneous antiphospholipid antibodies (aPL), which nonspecifically affect hemostasis by the presence of lupus anticoagulans (LA), anticardiolipin antibodies (aCL), antibodies against β2-glycoprotein-I (anti-β2GPI), but also non-criteria antibodies such as antibodies against β2-glycoprotein-I domain I (anti-DI), anti-phosphatidylserine/prothrombin (anti-PS/PT), anti-annexin V, and many others. The main target of the antibodies is the activated protein C (APC) system, the elimination of which can manifest itself as a thrombotic complication. The aim of this study was to determine the thrombogenicity of antibodies using a modified protein C-activated thrombin generation assay (TGA) on a group of 175 samples suspected of APS. TGA was measured with/without APC and the ratio of both measurements was evaluated (as for APC resistance), where a cut-off was calculated ≤4.5 (90th percentile) using 21 patients with heterozygous factor V Leiden mutation (FV Leiden heterozygous). Our study demonstrates the well-known fact that multiple positivity of different aPLs is a more severe risk for thrombosis than single positivity. Of the single antibody positivity, LA antibodies are the most serious (p value < 0.01), followed by aCL and their subgroup anti-DI (p value < 0.05). Non-criteria antibodies anti-annexin V and anti-PT/PS has a similar frequency occurrence of thrombogenicity as LA antibodies but without statistical significance or anti-β2GPI1 positivity. The modified TGA test can help us identify patients in all groups who are also at risk for recurrent thrombotic and pregnancy complications; thus, long-term prophylactic treatment is appropriate. For this reason, it is proving increasingly beneficial to include the determination antibodies in combination with modified TGA test.

摘要

抗磷脂综合征(APS)是一种高凝状态,伴有多种抗磷脂抗体(aPL)的存在,狼疮抗凝物(LA)、抗心磷脂抗体(aCL)、β2-糖蛋白 I 抗体(anti-β2GPI)等非特异性影响止血,但也有非标准抗体,如β2-糖蛋白 I 结构域 I 抗体(anti-DI)、抗磷脂酰丝氨酸/凝血酶原(anti-PS/PT)、抗膜联蛋白 V 等。抗体的主要靶标是活化蛋白 C(APC)系统,其消除可表现为血栓并发症。本研究旨在使用改良的蛋白 C 激活凝血酶原生成试验(TGA),在一组 175 例疑似 APS 的样本中,确定抗体的血栓形成性。TGA 分别在有/无 APC 的情况下进行测量,并评估两者测量的比值(APC 抵抗),使用 21 例杂合子因子 V 莱顿突变(FV Leiden heterozygous)患者的 90%分位数计算出≤4.5 的截止值(cut-off)。我们的研究证明了一个众所周知的事实,即多种不同 aPL 的阳性比单一阳性是血栓形成的更严重风险。在单一抗体阳性中,LA 抗体最为严重(p 值<0.01),其次是 aCL 及其亚组 anti-DI(p 值<0.05)。非标准抗体抗膜联蛋白 V 和抗 PT/PS 的血栓形成频率与 LA 抗体相似,但无统计学意义或 anti-β2GPI1 阳性。改良的 TGA 试验可以帮助我们识别所有组别的患者,这些患者也有复发性血栓形成和妊娠并发症的风险;因此,长期预防性治疗是合适的。出于这个原因,将抗体的测定与改良的 TGA 试验结合起来证明越来越有益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc52/9409152/65b11543cc2e/ijms-23-08973-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验